Given a passage, construct a question on the basis of the information present in the passage. Construct the question in such a way that (i) it is unambiguous, (ii) it is answerable from the passage, (iii) its answer is unique (iv) it answer uses text phrases from the passage. Avoid creating questions that (i) can't be answered correctly without actually understanding the passage and (ii) uses the same words or phrases given in the passage.

[EX Q]: This study was designed to determine the relevance of a proposed classification for advanced heart failure (HF). Profiles based on clinical assessment of congestion and perfusion at the time of hospitalization were compared with subsequent outcomes.', 'Optimal design of therapy and trials for advanced HF remains limited by the lack of simple clinical profiles to characterize patients.', "Prospective analysis was performed for 452 patients admitted to the cardiomyopathy service at the Brigham and Women's Hospital with a diagnosis of HF. Patients were classified by clinical assessment into four profiles: profile A, patients with no evidence of congestion or hypoperfusion (dry-warm, n = 123); profile B, congestion with adequate perfusion (wet-warm, n = 222); profile C, congestion and hypoperfusion (wet-cold, n = 91); and profile L, hypoperfusion without congestion (dry-cold, n = 16). Other standard predictors of outcome were included and patients were followed for the end points of death (n = 117) and death or urgent transplantation (n = 137) at one year.", 'Survival analysis showed that clinical profiles predict outcomes in HF. Profiles B and C increase the risk of death plus urgent transplantation by univariate (hazard ratio [HR] 1.83, p = 0.02) and multivariate analyses (HR 2.48, p = 0.003). Moreover, clinical profiles add prognostic information even when limited to patients with New York Heart Association (NYHA) class III/IV symptoms (profile B: HR 2.23, p = 0.026; profile C: HR 2.73, p = 0.009).
[EX A]: Does clinical assessment identify hemodynamic profiles that predict outcomes in patients admitted with heart failure?

[EX Q]: Few studies investigated the best method for removing stains from different types of resin-based composite restorations and compared them to the more recently introduced nanocomposites. This study compared the effect of four methods for stain removal from composite resins; finishing with Sof-lex disks, using pumice and brush, bleaching with 10% carbamide peroxide and 38% hydrogen peroxide.', 'Twenty disk specimens were prepared. Specimens were immersed in a staining solution for 3\xa0weeks. The stained surfaces of five specimens from each RBC material were treated with one of the treatment procedures. Colorimetric measurements were taken using spectrophotometer prior to and after staining, and then repeated after surface treatments. Color difference values were calculated.', "One-way ANOVA indicated significant differences in color change of the three composite resin materials following staining. Filtek Z250 showed the least susceptibility to discoloration followed by Renamel, Filtek Supreme was the material most prone to discoloration. Two-way ANOVA and Tukey's Post Hoc showed that all stain removing procedures except polishing with pumice, were able to return Filtek Z250 to clinically acceptable color difference. While bleaching with 38% carbamide peroxide was not effective with Renamel. Only pumice and 10% carbamide peroxide were able to return Renamel to clinically acceptable color difference.
[EX A]: Do the effectiveness of four methods for stain removal from direct resin-based composite restorative materials?

[EX Q]: All-oral regimens combining different classes of direct-acting antivirals (DAA) are highly effective for treatment of patients with chronic hepatitis C. NS5A inhibitors will likely form a component of future interferon-sparing treatment regimens. However, despite their potential, the detailed mechanism of action of NS5A inhibitors is unclear. To study their mechanisms, we compared their kinetics of antiviral suppression with those of other classes of DAA, using the hepatitis C virus genotype 1a cell culture-infectious virus H77S.3.', 'We performed detailed kinetic analyses of specific steps in the hepatitis C virus life cycle using cell cultures incubated with protease inhibitors, polymerase inhibitors, or NS5A inhibitors. Assays were designed to measure active viral RNA synthesis and steady-state RNA abundance, polyprotein synthesis, virion assembly, and infectious virus production.', 'Despite their high potency, NS5A inhibitors were slow to inhibit viral RNA synthesis compared with protease or polymerase inhibitors. By 24 hours after addition of an NS5A inhibitor, polyprotein synthesis was reduced <50%, even at micromolar concentrations. In contrast, inhibition of virus release by NS5A inhibitors was potent and rapid, with onset of inhibition as early as 2 hours. Cells incubated with NS5A inhibitors were rapidly depleted of intracellular infectious virus and RNA-containing hepatitis C virus particles, indicating a block in virus assembly.
[EX A]:
Do kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors?